Brokers Issue Forecasts for Disc Medicine Q1 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Disc Medicine in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.01) for the quarter. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Leerink Partnrs also issued estimates for Disc Medicine’s Q2 2025 earnings at ($1.16) EPS and Q3 2025 earnings at ($1.44) EPS.

Several other research analysts have also recently issued reports on IRON. HC Wainwright restated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Wedbush reiterated an “outperform” rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a report on Tuesday, November 5th. Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Finally, TD Cowen started coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a “buy” rating on the stock. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $89.10.

Disc Medicine Price Performance

IRON opened at $55.34 on Monday. The stock’s 50 day simple moving average is $57.70 and its 200 day simple moving average is $55.75. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -13.90 and a beta of 0.73. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $73.66.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $66.01, for a total value of $844,333.91. Following the sale, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Pamela Stephenson sold 3,137 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the transaction, the insider now owns 69,529 shares of the company’s stock, valued at $3,794,892.82. The trade was a 4.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,080 shares of company stock valued at $4,523,520 in the last three months. Company insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock worth $308,000 after acquiring an additional 396 shares during the period. Sterling Capital Management LLC raised its stake in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after buying an additional 503 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after acquiring an additional 593 shares during the period. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.